|
[1]
|
Hoch, E., et al. (2019) How Effective and Safe Is Medical Cannabis as a Treatment of Mental Disorders? A Systematic Review. European Archives of Psychiatry and Clinical Neuroscience, 269, 87-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
韩莎莎, 张殿杭, 李丽. 大麻二酚的药理研究进展[J]. 药物资讯, 2019, 8(3): 49-55.
|
|
[3]
|
Ahmed, A.I., van den Elsen, G.A., Colbers, A., et al. (2015) Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of Delta-9-Tetrahydrocannabinol in Older Persons with Dementia. Psy-chopharmacology, 232, 2587-2595. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Van den Elsen, G.A., Ahmed, A.I., Verkes, R.J., Feuth, T., et al. (2015) Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. The American Journal of Geriatric Psychiatry, 23, 1214-1224. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Van den Elsen, G.A.H., Ahmed, A.I.A., Jan Verkes, R., et al. (2015) Efficacy and Safety of Delta-9-Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Randomized Controlled Trial. Alzheimer’s Dement, 11, 469-470. [Google Scholar] [CrossRef]
|
|
[6]
|
Allsop, D.J., Copeland, J., Lintzeris, N., Dunlop, A.J., et al. (2014) Nabiximols as an Agonist Replacement Therapy during Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71, 281-291. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Levin, F.R., et al. (2011) Dronabinol for the Treatment of Cannabis Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Drug Alcohol Depend, 116, 142-150. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Levin, F.R., Mariani, J.J., Pavlicova, M., et al. (2016) Dronabinol and Lofexidine for Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Drug Alcohol Depend, 159, 53-60. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Trigo, J.M., Soliman, A., Quilty, L.C., et al. (2018) Nabiximols Combined with Motivational Enhancement/Cognitive Behavioral Therapy for the Treatment of Cannabis Dependence: A Pilot Randomized Clinical Trial. PLoS ONE, 13, e0190768. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Trigo, J.M., Lagzdins, D., Rehm, J., et al. (2016) Effects of Fixed or Self Titrated Dosages of Sativex on Cannabis Withdrawal and Cravings. Drug Alcohol Depend, 161, 298-306. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Bisaga, A., Sullivan, M.A., Glass, A., et al. (2015) The Effects of Dronabinol during Detoxification and the Initiation of Treatment with Extended Release Naltrexone. Drug Alcohol Depend, 154, 38-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Jicha, C.J., Lofwall, M.R., Nuzzo, P.A., et al. (2015) Safety of Oral Dronabinol during Opioid Withdrawal in Humans. Drug Alcohol Depend, 157, 179-183. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Boggs, D.L., Surti, T., Gupta, A., et al. (2018) The Effects of Cannabidiol (CBD) on Cognition and Symptoms in Outpatients with Chronic Schizophrenia a Randomized Placebo Controlled Trial. Psychopharmacology, 235, 1923-1932. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
McGuire, P., Robson, P., Cubala, W.J., et al. (2018) Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 175, 225-231. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Jetly, R., Heber, A., Fraser, G., et al. (2015) The Efficacy of Nabilone, a Synthetic Cannabinoid, in the Treatment of PTSD Associated Nightmares: A Preliminary Randomized, Dou-ble-Blind, Placebo-Controlled Cross-Over Design Study. Psychoneuroendocrinology, 51, 585-588. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Cooper, R.E., Williams, E., Seegobin, S., et al. (2017) Canna-binoids in Attention-Deficit/Hyperactivity Disorder: A Randomised-Controlled Trial. European Neuropsychopharmacology, 27, 795-808. [Google Scholar] [CrossRef] [PubMed]
|